article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Investing in areas that have demonstrated a good track record of success for similar companies is a simple way to reduce risk, but in 2022, companies should be careful of investing in overly populated life sciences clusters, which might be too competitive.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

To build an advanced pharmaceutical manufacturing cluster in the Richmond-Petersburg area, the Alliance for Building Better Medicine aims to support the early growth of local pharmaceutical manufacturers. billion in equity since it started in 2014. million as part of the Build Back Better Regional Challenge.